The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen

[1]  T. Acker,et al.  Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. , 2010, Cancer research.

[2]  William C Hahn,et al.  Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. , 2009, Cancer cell.

[3]  W. Kaelin,et al.  A Feedback Loop Involving the Phd3 Prolyl Hydroxylase Tunes the Mammalian Hypoxic Response In Vivo , 2009, Molecular and Cellular Biology.

[4]  G. Song,et al.  Role of hypoxia in the hallmarks of human cancer , 2009, Journal of cellular biochemistry.

[5]  Howard Y. Chang,et al.  Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. , 2009, Cancer cell.

[6]  G. Semenza,et al.  Regulation of cancer cell metabolism by hypoxia-inducible factor 1. , 2009, Seminars in cancer biology.

[7]  S. Fox,et al.  Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Kaelin,et al.  Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. , 2008, Molecular cell.

[9]  K. Takeda,et al.  Role and regulation of prolyl hydroxylase domain proteins , 2008, Cell Death and Differentiation.

[10]  J. Pouysségur,et al.  PHDs overactivation during chronic hypoxia “desensitizes” HIFα and protects cells from necrosis , 2008, Proceedings of the National Academy of Sciences.

[11]  S. Fox,et al.  BNIP3 as a Progression Marker in Primary Human Breast Cancer; Opposing Functions in In situ Versus Invasive Cancer , 2007, Clinical Cancer Research.

[12]  J. Nielsen,et al.  Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity , 2006, Proceedings of the National Academy of Sciences.

[13]  K. Takeda,et al.  Placental but Not Heart Defects Are Associated with Elevated Hypoxia-Inducible Factor α Levels in Mice Lacking Prolyl Hydroxylase Domain Protein 2 , 2006, Molecular and Cellular Biology.

[14]  Manuela Milani,et al.  Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer , 2006, Clinical Cancer Research.

[15]  P. Ratcliffe,et al.  Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation. , 2006, The Biochemical journal.

[16]  A. Harris,et al.  Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD‐1, PHD‐2, PHD‐3 and FIH in normal and neoplastic human tissues , 2005, Histopathology.

[17]  S. Fox,et al.  The Androgen Receptor Is Significantly Associated with Vascular Endothelial Growth Factor and Hypoxia Sensing via Hypoxia-Inducible Factors HIF-1a, HIF-2a, and the Prolyl Hydroxylases in Human Prostate Cancer , 2005, Clinical Cancer Research.

[18]  E. Stanbridge,et al.  Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. , 2005, Cancer research.

[19]  P. Maxwell.  The HIF pathway in cancer. , 2005, Seminars in cell & developmental biology.

[20]  W. Kaelin,et al.  Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. , 2005, Cancer cell.

[21]  D. Generali,et al.  Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. , 2005, Endocrine-related cancer.

[22]  P. Bonnier,et al.  Overexpression of hypoxia‐inducible factor HIF‐1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients , 2005, International journal of cancer.

[23]  A. Harris,et al.  Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression , 2004, British Journal of Cancer.

[24]  A. Harris,et al.  Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.

[25]  P. V. van Diest,et al.  Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma , 2003, Cancer.

[26]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[27]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[28]  P. Bruzzi,et al.  Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer , 2001, British Journal of Cancer.

[29]  A. Harris,et al.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[31]  J. M. Arbeit,et al.  Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth , 2000 .

[32]  M. Brizzi,et al.  p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[34]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[35]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[36]  A. Aletras,et al.  Inhibition of Angiogenesis by Anthracyclines and Titanocene Dichloride a , 1994, Annals of the New York Academy of Sciences.

[37]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[38]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .